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Abstract Background Glucagon-like peptide-1 receptor
agonists (GLP-1 RA) added to insulin in type 2 diabetes
patients have shown to lower body weight, improve gly-
caemic control and reduce total daily insulin dose in short
term studies, although the individual response greatly
varies. Objective To evaluate GLP-1 RA treatment on body
weight, glycaemic control and total daily insulin dose in
obese, insulin-using type 2 diabetes patients after 2 years
follow-up in a real life setting and to explore a possible
relation with eating behaviour. Setting The Martini
Hospital and the University Medical Center in Groningen
in the Netherlands. Methods Eligible patients were at least
18 years of age, were on insulin therapy and obese
(BMI[ 30 kg/m2), started GLP-1 RA treatment. At base-
line eating behaviour was classified according to the vali-
dated Dutch Eating Behaviour Questionnaire. A 2 years
follow-up was performed. Main outcome measures Body
weight, HbA1c and total daily insulin dose. Results 151
Patients started with exenatide or liraglutide. 120 patients
completed the 2 years follow-up. From baseline to 2 years,
body weight (mean ± SD) changed from 117.9 ± 22.1 to
107.9 ± 22.9 kg (P\ 0.0001), HbA1c (median, IQR)
changed from 7.9 (7.2–8.9) to 7.6 (6.9–8.3) % [63 (55–74)
to 60 (52–67) mmol/mol] (P\ 0.0001), total daily insulin
dose changed from 90 (56–150) to 60 (0–100) Units/day
(P\ 0.0001). Weight change differed between eating
behaviour groups (P\ 0.001) in which external eating
behaviour (n = 17) resulted in the smallest decline
(-3.1 %) and restrained (n = 41) in the greatest
(-10.3 %) in comparison with emotional (n = 37,
-8.5 %) and indifferent (n = 25, -9.6 %) eating beha-
viours. Conclusion Two year of GLP-1 RA treatment
resulted in a sustained reduction of weight, HbA1c and
total daily insulin dose in obese, insulin-using type 2 dia-
betes patients in a real life setting. Largest weight loss was
achieved in patients with a predominant restraint eating
pattern while a predominant external eating pattern resulted
in the smallest weight reduction.
Keywords Diabetes mellitus  Eating behaviour  GLP-1
receptor agonist  Insulin therapy  Weight loss
Impacts on practice
• Addition of glucagon-like peptide-1 receptor agonists
(GLP-1 RA) to obese, insulin-treated type 2 diabetes
patients markedly reduces body weight, HbA1c and
daily insulin doses or insulin discontinuation in a long
term clinically based setting.
• Preexistent eating behavior modifies the amount of
weight loss and assessment of eating behavior may help
to identify those patients who will benefit most from
GLP-1 RA.
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Introduction
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are
used for weight loss and insulin dose reduction in obese
insulin-using type 2 diabetic patients [1–7]. However, in
daily practice the individual response of weight loss to
GLP-1 RA varies greatly [8]. A recent Dutch cohort study
[1] confirmed two earlier clinical based observational
studies [2, 3] of a more than expected weight reduction
than generally reported in randomized controlled trials [4–
7]. A high BMI and longer diabetes duration at start of
treatment has been identified as predictors of greater
weight loss [8] but other factors involved are unknown.
A plausible mechanism by which GLP-1 RA may
induce weight loss is by suppressing appetite signalling in
the brain and increasing satiety, leading to a reduced food
intake [9, 10]. GLP-1 receptors are present in the central
nervous system suggesting direct actions of GLP-1 in the
brain [11]. GLP-1 infusions can enhance satiety and reduce
energy intake in type 2 diabetes patients [12]. Furthermore,
GLP-1 RA attenuates binge eating in obese patients [13],
suggesting a role of GLP-1 RA in certain eating types.
The psychology of eating distinguishes three main types
of eating behaviours i.e. predominant external, emotional,
and restrained eating patterns. External eaters are triggered
in response to sensory stimuli irrespective of satiety [14].
Emotional eaters are driven by stress and emotions while the
natural response would be to loose appetite [15]. Restrained
eaters intentionally limit food intake to control weight.
However, the self-imposed food restriction in restrained
eaters is recognised by the body as true food shortage which
goes into the starvation mode thus increasing hunger and
lowering metabolic rate [16]. All these three eating beha-
viour patterns have been implicated in the risk of developing
obesity [17]. A possible relation between eating patterns and
response to GLP-1 RA has never been studied in patients
with type 2 diabetes on insulin.
Aim of the study
To explore the role of eating behaviour on changes in
weight, glycaemia and total daily insulin dose (TDD) in
obese, insulin-using type 2 diabetes patients in clinical
practise.
Ethical approval
The study was notified by the local ethics committee and
was performed in accordance with the principles of the
Declaration of Helsinki. All patients consented with the
protocol including regular outpatient follow-up (FU) and
the off-label use of GLP-1 RA with insulin.
Methods
Study design and participants
This prospective observational cohort study recruited
patients at the Martini Hospital Groningen and the
University Medical Center Groningen in the Netherlands.
Eligible subjects were obese (BMI[ 30 kg/m2), insulin-
using type 2 diabetes with a long-standing wish of weight
reduction. They were [18 years of age, had a diabetes
duration for[1 year and were receiving long-, intermedi-
ate or short-acting insulin (insulin glargine, insulin detemir,
NPH insulin, regular insulin, insulin aspart, insulin lispro,
or mixed insulin) with or without oral antidiabetic drugs
(OAD). Patients were excluded if they had recurrent
hypoglycaemia, a history of bariatric surgery, a history of
pancreatitis, or had been treated with anti-obesity medi-
cation. The goals of GLP-1 RA treatment were weight loss
and insulin dose reduction. The first patient started GLP-1
RA in January 2008 and the last patient started in January
2011. The study sample size was reflective of the number
of eligible patients during this period.
Study protocol
GLP-1 RA treatment was initially given with exenatide,
dose increased to 10 lg twice daily, which was at the start
of the study in January 2008 the only available GLP-1 RA
in the Netherlands. In May 2009, liraglutide was the second
GLP-1 RA marketed in the Netherlands and preferred by
patients because of its once daily administration, dose
increased to 1.8 mg per day. At that time it was decided to
study both GLP-1 RA with the intention to make a between
GLP-1 RA drug comparison on outcomes.
No specific dietary restrictions were given for the study
other than that all patients had received previous instruc-
tions and education on a healthy diet and lifestyle in
accordance with the Dutch standards of care. FU was done
at 6 weeks, 3, 6, 9, 12, 18 months, and after 2 years. At all
study visits HbA1c (%), body weight (kg) and blood
pressure were measured (mmHg), adherence to GLP-1 RA
therapy, TDD (U/day), and OAD were documented.
Adverse events were also noted including hypoglycaemic
events. Hypoglycaemia was defined as major if the patient
needed assistance for treatment of hypoglycaemia. At the
start and after 2 years of FU serum creatinine (umol/l),
triglycerides (mmol/l), HDL-, LDL-, and total cholesterol
(mmol/l) were measured.
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Dutch Eating Behaviour Questionnaire
At baseline, eating behaviour was classified according to
the validated Dutch Eating Behaviour Questionnaire
(DEBQ) [18]. The DEBQ has a scale on restrained eating
(e.g. ‘‘Do you try to eat less at mealtimes than you would
like to eat?’’) and two separate scales on overeating ten-
dency: emotional eating (e.g. ‘‘Do you have a desire to eat
when you are irritated?’’) and external eating (e.g. ‘‘If food
smells and looks good, do you eat more than usual?’’) [18].
Patients were classified according to their predominant
eating pattern as defined by van Strien [18] as restrained,
emotional, external or indifferent eaters.
Outcome measures
The primary outcome variable was change in weight after
2 years FU. Secondary outcome measures were change in
HbA1c and TDD after 2 years FU. Safety parameters
included: hypoglycaemia, nausea, vomiting, diarrhoea, and
hospital admission.
Statistical analysis
Data are presented as numbers and percentage. Variables
with a normal distribution are presented as mean ± SD and
otherwise as median and inter-quartile range (IQR). Sta-
tistical analyses were performed using the Statistical
Package for Social Sciences version 20 (SPSS Inc., Chi-
cago, Iln, USA). Variables at baseline and after 2 years of
treatment were compared using the Students paired t test
and a Wilcoxon test were required. To compare groups, the
Fisher exact or a one way ANOVA was used (or a Kurskall
Wallis test if necessary), with logarithmic transformation
for non-normally distributed variables and a post hoc
Bonferroni for multiple comparisons if significant. To
compare multivariate means between groups, a MANOVA
was used. Backward multiple linear stepwise regression
was used to identify variables independently (P\ 0.100)
associated with change in weight, HbA1c, and TDD.
Logistic regression was used to identify variables inde-
pendently associated with stopping insulin treatment. Since
the duration of diabetes and BMI may be potential con-
founders, subgroup analyses were performed by dividing
the study cohort into tertiles of these variables. A P\ 0.05
was considered statistically significant.
Results
One hundred and fifty-one obese, insulin-using type 2
diabetes patients were started on GLP-1 RA therapy. One
hundred and twenty patients completed the 2 years of FU,
21 stopped B6 months mainly due to side-effects (mostly
gastrointestinal) and because they experienced no effects
on weight and insulin dose. Nine patients were lost to FU,
and one patient died due to myocardial infarction. The
present analysis was done in those patients (n = 120) that
completed 2 year FU after the initial prescription.
Clinical characteristics
Table 1 shows the clinical characteristics at baseline and
after 2 years FU. Mean age was 58.4 ± 8.1 years, 52.5 %
were females, and the median diabetes duration was 10.0
(7.0–16.0) years. From baseline to 2 years, body weight
(mean ± SD) changed from 117.9 ± 22.1 to 107.9 ±
22.9 kg (P\ 0.0001), HbA1c (median, IQR) changed from
7.9 (7.2–8.9) to 7.6 (6.9–8.3) mmol/l [63 (55–74) to 60
(52–67) mmol/mol] (P\ 0.0001), TDD changed from 90
(56–150) to 60 (0–100) Units/day (P\ 0.0001) and 30 %
(n = 36) of the patients were able to stop insulin treatment.
A total of 57 patients (47.5 %) experienced side effects,
mostly gastrointestinal including nausea and vomiting
(n = 45), diarrhoea (n = 3), constipation (n = 1). Two
patients had to be hospitalized because of acute renal
failure following severe dehydration due to a lack of
intake. No severe hypoglycaemia occurred.
Exenatide and liraglutide treatment
Of the 120 patients completing the 2 years FU, 73 patients
started with exenatide and 56 patients started with liraglutide.
A total of 18 patients switched from exenatide to liraglutide
when liraglutide became available and one patient switched
from liraglutide to exenatide. Subgroup analysis revealed no
differences in clinical characteristics of patients using exe-
natide or liraglutide, according to treatment at baseline and
after 2 years FU (Supplemental table S1). Exenatide and
liraglutide showed similar weight losses [exenatide (mean,
SD) -11.6 ± 8.3 kg vs liraglutide -8.8 ± 7.5 kg, P =
0.058], similar reductions in HbA1c (exenatide -0.54 ±
1.4 % vs liraglutide -0.43 ± 1.0 %, P = 0.641), similar
reductions in insulin dose [exenatide (median, IQR) -31
(-60 to -7) U/day vs liraglutide -45 (-63 to -15) U/day,
P = 0.119] all according to the treatment received at 2 years
FU. Sinceweight loss,HbA1c and insulin dose reductionwere
similar, the two GLP-1 treatments, exenatide and liraglutide,
were combined in the further analysis.
Change in weight
The overall changes in weight according to different pre-
defined groups (diabetes duration, BMI and eating beha-
viour) are given in Fig. 1a–c. There were no significant
differences in weight changes among diabetes duration
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tertiles. Across baseline BMI tertiles, a greater weight loss
was observed in patients with a higher baseline BMI
(36–40 and[40 kg/m2) which was significant at 9 months
(P = 0.03), 12 months (P = 0.025), 18 months (P =
0.010) and 2 years FU (P = 0.021). According to eating
behaviour, the smallest decline was observed in external
eaters which was significant at 9 months (P = 0.032),
12 months (P = 0.010), 18 months (P = 0.001), and
2 years FU (P = 0.001).
Multiple linear stepwise regression analysis was used to
identify the predictors of the change in weight at 2 years
FU. Only baseline BMI, beta (95 % CI) -0.230 (-0.399 to
-0.062, P = 0.008) was significantly associated with
weight loss. Sex, age, baseline HbA1c, baseline TDD, and
diabetes duration were not significant and were excluded
from the model.
Glycaemic control
The overall change in HbA1c (geometric mean and 95 %
CI) according to the predefined subgroups are given in
Fig. 1d–f. Across diabetes duration tertiles, a lower HbA1c
was observed in patients with a shorter diabetes duration
(\8 years) which was significant at 9 months (P = 0.001),
12 months (P = 0.003), 18 months (P = 0.001), and
2 years FU (P = 0.002). There were no significant differ-
ences in HbA1c among baseline BMI tertiles and eating
behaviour groups.
Multiple linear stepwise regression analysis was used to
identify the factors (eating behaviour excluded) associated
with change in HbA1c at 2 years FU. Only baseline HbA1c
beta (95 % CI) -0.587 (-0.733 to -0.441, P\ 0.0001),
and diabetes duration beta 0.191 (0.043–0.338, P = 0.011)
Table 1 Clinical characteristics at baseline and change after 2 years
Characteristics At baseline After 2 years P valuea
N 120
Female (n) 63 (52.5 %)
Age (years) 58.4 (8.1)
Diabetes duration (years) 10 (7.0–16.0)
BMI (kg/m2) 39.5 (6.5) 36.1 (6.2) \0.0001
Weight (kg) 117.9 (22.1) 107.9 (21.9) \0.0001
HbA1c (%) 7.9 (7.2–8.9) 7.6 (6.9–8.3) \0.0001
HbA1c (mmol/l) 63 (55–74) 60 (52–67)
Total cholesterol (mmol/l) 4.0 (3.6–4.6) 3.8 (3.4–4.6) 0.011
HDL (mmol/l) 1.1 (0.9–1.3) 1.1 (0.9–1.3) 0.834
LDL (mmol/l) 2.1 (1.6–2.5) 2.1 (1.6–2.5) 0.601
Triglycerides (mmol/l) 1.94 (1.47–3.08) 1.77 (1.31–2.35) \0.0001
Serum creatinine (umol/l) 74.5 (66.0–88.8) 74.0 (62.0–85.0) 0.006
Systolic blood pressure (mmHg) 140.0 (130–148) 133.0 (120–140) \0.0001
Diastolic blood pressure (mmHg) 80.0 (75.0–88.0) 80.0 (70.0–80.0) \0.0001
Diabetes treatment
Insulin therapy (n) 120 (100 %) 84 (69.4 %) \0.0001
Insulin dose (U/day) (all patients, n = 120) 90 (56–150) 60.0 (0–100) \0.0001
Insulin dose (U/kg/day) (all patients, n = 120) 0.75 (0.47–1.33) 0.54 (0.00–0.87) \0.0001
Insulin dose (U/day) (patients using insulin after 2 years, n = 84) 119 (73–182) 80 (55–124) \0.0001
Insulin dose (U/kg/day) (patients using insulin after 2 years, n = 84) 1.01 (0.65–1.47) 0.71 (0.53–1.11) \0.0001
Oral therapy
No oral therapy (n) 13 (10.8 %) 16 (13.3 %) 0.453
1 oral therapy (n) 80 (66.7 %) 86 (71.7 %) 0.307
2 oral therapy (n) 27 (22.5 %) 18 (15 %) 0.049
GLP-1 treatment
Exenatide (n) 73 (60.8 %) 56 (46.7 %)
Liraglutide (n) 47 (39.2 %) 64 (53.3 %)
Data are expressed as number (%) or means (SD) or if not normal distributed as median IQR
a P\ 0.05 indicates statistical significance
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were independently associated with changes of HbA1c.
Sex, age, baseline BMI, and baseline TDD were not sig-
nificant and were excluded from the model. Moreover,
there was no relation between change in weight (kg) and
change in HbA1c (%) at 2 years FU, Pearson correlation
0.013, P = 0.887.
Insulin dose
The decrease in TDD throughout the 2 years of FU
(Table 1) across the diabetes duration tertiles, was lower in
patients with a shorter diabetes duration (\8 years)
(P\ 0.0001 at every point of FU). Across baseline BMI
tertiles, patients with a lower BMI (36\ kg/m2) used
significantly (P\ 0.05) less Units/day at every point of
FU. The change in TDD did not differ between baseline
BMI tertiles and eating behaviour groups.
Multiple linear stepwise regression analysis was used to
identify predictors (except for eating behaviour) of the
change in TDD at 2 years FU. Only baseline TDD, beta
(95 % CI) -0.450 (-0.279 to -0.622, P\ 0.0001) and
diabetes duration, beta 0.176 (0.005–0.347, P = 0.044)
were significant associated with changes of TDD, if tested
stepwise. Sex, age, baseline HbA1c, and baseline BMI
were not significant and were excluded from the model. In
the logistic regression analysis, only diabetes duration
(years) with an odds-ratio (95 % CI) of 0.893
(0.814–0.979, P = 0.016) and TDD (Units) with an odds-
ratio of 0.976 (0.964–0.988, P\ 0.0001) were associated
with stopping insulin treatment, whereas sex, age, baseline
Fig. 1 Change in weight (kg) according to duration of diabetes (a),
baseline BMI (b) and eating behaviour group (c); HbA1c (%)
according to duration of diabetes (d), baseline BMI (e) and eating
behaviour group (f) in the patients (n = 120) who completed the
2 years follow-up. Data are presented as mean change in weight
(SEM) and geometric mean (95 % CI). Asterisk denotes P\ 0.05 to
P\ 0.01 from other groups
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HbA1c, and baseline BMI were not independently
associated.
Eating behaviour
In each group of eating behaviour, body weight was sig-
nificantly reduced after 2 years FU: external (n = 17)
117.8 ± 18.7 kg to 114.4 ± 20.4 kg (-3.1 %, P\ 0.022),
emotional (n = 37) 113.8 ± 19.7 kg to 103.9 ± 19.0 kg
(-8.5 %, P\ 0.001), restrained (n = 41) 123.8 ± 22.7 kg
to 111.3 ± 22.5 kg (-10.3 %, P\ 0.001), indifferent
(n = 25) 114.6 ± 25.4 kg to 103.8 ± 24.8 kg (-9.6 %,
P\ 0.001). Weight change at 2 years FU differed signif-
icantly between types of eating behaviour (Fig. 2,
P\ 0.001). After correction for differences between dif-
ferent types of eating behaviour (Supplemental table S1) in
baseline BMI, diabetes duration, baseline HbA1c, and
baseline TDD, the differences in change in weight at
2 years FU remained significant (MANOVA, P\ 0.001).
Changes in HbA1c and TDD at 2 years FU did not differ
significantly between types of eating behaviour. If tested
with a one way ANOVA and post hoc Bonferroni pre-
dominant external eaters showed less change in weight
which was significant at 9 months (P = 0.032), 12 months
(P = 0.010), 18 months (P = 0.010) and 2 years FU
(P = 0.010) compared to emotional, restrained and indif-
ferent predominant eaters.
Discussion
The current study demonstrated that GLP-1 RA given to
obese, insulin-using type 2 diabetes patients resulted in a
marked weight loss, improved glycaemic control and con-
siderably reduced daily insulin doses. These changes were
most prominent during the first 3 months of GLP-1 RA
treatment, then gradually tapered and sustained during
2 years of follow-up. Thereby these findings confirm and
expand other clinical based cohort studies [1–3] that showed
a more than average weight loss on GLP-1 RA than gen-
erally reported [4–7]. In addition, we found that pre-existing
eating behaviour influenced GLP1 RA induced weight loss,
which was obvious in restrained and indifferent eaters and
mitigated in patients with an external eating trait.
GLP-1 RA have consistently shown to reduce weight
and improve glycaemic control in insulin-using type 2
diabetes patients, however variable responses have been
reported [4–7]. Two systematic reviews mentioned a -0.9
to -5.6 kg and a -1.5 to -4.9 kg (-3.2 kg on average)
weight loss when GLP-1 RA was added to insulin in type 2
diabetes patients [6, 7]. Our study demonstrated a much
larger weight loss that corresponded with the amount of
weight reduction of -6.5 (±0.8) kg at 26 weeks [2], -12.8
(±7.5) kg [3] and -14.3 (±9.5) kg [1] at 52 weeks at the
consecutive time points in our study.
The GLP-1 RA therapy was given either with exenatide,
an exendin-based GLP-1 receptor agonist, or with liraglu-
tide, a human GLP-1 analogue, for reasons connected to
the clinical based observational nature of our study (see
‘‘Methods’’ section). A comparison of the efficacy of both
treatment options disclosed no meaningful differences in
outcome of our study. This is in conjunction with the RCT
that head-to-head compared exenatide and liraglutide
(LEAD-6 trial) [19] showing similar weight loss of both
drugs. The LEAD-6 trial found larger HbA1c reductions
with liraglutide than with exenatide but in a quite different
type 2 diabetic patient population only using OAD treat-
ment and no insulin.
Little is known about the factors that determine the
amount of weight loss by GLP-1 RA treatment. In a post
hoc analysis on a previous RCT, the greatest reductions in
weight and also HbA1c were seen in the more obese
patients (BMI[ 30 kg/m2) and the longest diabetes dura-
tion ([13 years) [8]. In conjunction, we found the greatest
weight reductions in the most obese patients
(BMI[ 36 kg/m2) and a non-significant tendency for a
longer diabetes duration ([13 years). Thus the substantial
weight loss that we and the few other studies observed,
may have resulted from higher baseline BMI that amply
exceeded 35 kg/m2 in all [1–3]. A confounding factor may
have been the selection of patients as we included those in
Fig. 2 Individual changes in weight at 2 years of follow-up accord-
ing to eating behaviour category. Asterisk denotes P\ 0.05 from
other groups
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whom overweight complicated their diabetes with weight
reduction as the primary treatment goal. Therefore a
selection bias may have occurred as some patients who did
not experience an early clinical benefit from GLP-1 RA
discontinued the study. Since our study was observational
in nature with no control group, it is difficult to determine
the exact weight loss attributable to the GLP-1 RA treat-
ment. Notwithstanding that the currently observed weight
loss was that what genuinely can be achieved in outpatient
clinical setting, as recently reported [1].
To our knowledge, this is one of the first studies that
investigated eating behaviour in relation to efficacy of GLP-
1 RA administration showing that restrained and indifferent
eaters obviously lost weight and external eaters had the
smallest reductions in weight loss. There is only one small
Japanese study in obese type 2 diabetes patients (n = 16)
that assessed eating scores and traits in relation to the GLP-1
RA, showing that amount of weight loss correlated with a
promptly reduced score for the sense of hunger that showed
an interaction with external eating behaviour [20].
There are a few studies that might provide a patho-
physiological basis by which external eating mitigated
weight reduction. First, in an functional magnetic reso-
nance imaging (fMRI) study healthy obese men were
treated with exenatide or saline infusion in a blinded
fashion and shown food pictures (external eating stimulus).
Only in those subjects who showed C 10 % reduction in
caloric intake (responders), effects of exenatide were
observed on the fMRI in the hypothalamus [21]. Second, in
another fMRI study the brain responses to food pictures
were higher in obese non-diabetic and type 2 diabetes than
lean subjects [10]. GLP-1 RA administration decreased the
brain responses to food pictures and food intake in the
obese non-diabetic and type 2 diabetes subjects and a lower
reduction in food picture-induced brain activation (external
stimulus) led to a smaller decrease in food intake [10]. In
terms of external eating behaviour this means that persis-
tent brain activation was marginally diminished by GLP-1
RA and did not change food intake. Hence from these
experimental studies, we suppose that a higher proportion
of external eaters could have diminished or lacking effects
of GLP1-RA on the brain.
The DEBQ is a widely used questionnaire that was
developed to measure the three eating behaviour styles
which are generally accepted as the psychological basis of
overeating. It has been shown that patients with obesity,
anorexia nervosa, and healthy controls all have a different
eating behaviour as measured by the DEBQ [22]. Inter-
estingly, reduced GLP-1 levels in bulimia nervosa have
been associated with binge-eating episodes [23]. As binge-
eating is common in restrained and in emotional eaters, this
may give an indication why these eating behaviour patterns
in our study benefited from GLP-1 RA treatment.
The diabetes treatment was individually tailored by the
treating physicians (JDL, KH, KMT, SHJD). Despite the
limitation that no strict treatment protocol for glycaemic
control was used, net glycaemia improved, TDD decreased
with an average of 30 U/day with 30 % of patients stop-
ping insulin and no severe episodes of hypoglycaemia.
Thus this clinical based study provided an impression of
the expected benefit on HbA1c and insulin dose reduction
that can be achieved by GLP1 RA treatment in daily
practise.
Conclusion
This observational cohort study showed that GLP-1 RA
treatment resulted in a sustained reduction of weight,
HbA1c and TDD in obese insulin-using type 2 diabetes
patients in a real life setting. Largest weight loss was
achieved in patients with a predominant restraint eating
pattern while a predominant external eating pattern resulted
in the smallest weight reduction. The finding that pre-ex-
isting eating behaviour modulated the effects of GLP1-RA
on weight loss deserves further study.
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